TY - JOUR
T1 - Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients
AU - Soliman, Amr S.
AU - Bondy, Melissa
AU - Webb, Charity Renee
AU - Schottenfeld, David
AU - Bonner, Joseph
AU - El-Ghawalby, Nabih
AU - Soultan, Ahmed
AU - Abdel-Wahab, Mohamed
AU - Fathy, Omar
AU - Ebidi, Gamal
AU - Zhang, Qing
AU - Greenson, Joel K.
AU - Abbruzzese, James L.
AU - Hamilton, Stanley R.
PY - 2006/9/15
Y1 - 2006/9/15
N2 - Variations in genetic mutations in pancreatic carcinoma between different populations have not been studied extensively, especially in developing countries where pancreatic cancer is rare. We studied the molecular pathology of 44 pancreatic carcinomas from patients residing in a heavily polluted region in the Nile River delta and compared the findings with tumors from 44 United States (US) patients. We evaluated K-ras mutations in codon 12, p53 mutations in exons 5-8, and Gadd45a mutations in exons 1 and 4. Overall, rates of K-ras, p53 and Gadd45 mutations were not statistically different in tumors of patients from Egypt and the US (67.4 vs. 63.4%; 27.3 vs. 36.4% and 9.1 vs. 4.5%, respectively). However, there were distinct differences in the specific types of K-ras and p53 mutations between the 2 groups. In K-ras, G → T transversion mutation was more frequent in the tumors from Egypt than from the US (58.6 vs. 26.9%), whereas G → C transversion was detected in 26.9% of US tumors but none from Egypt (p = 0.003). We also found a trend toward differences in the p53 exons in which mutations occurred, with higher frequency of exon 5 mutation and lower frequency of exon 6 mutation in Egyptian tumors. Logistic regression showed that K-ras G → T transversion mutations and p53 exon 6 mutations were predicted by the country of residence of the patients. Our study identifies that there are differences in the types of mutations found in tumors from pancreatic carcinoma patients in Egypt and the US, and suggests that environmental factors may explain these differences.
AB - Variations in genetic mutations in pancreatic carcinoma between different populations have not been studied extensively, especially in developing countries where pancreatic cancer is rare. We studied the molecular pathology of 44 pancreatic carcinomas from patients residing in a heavily polluted region in the Nile River delta and compared the findings with tumors from 44 United States (US) patients. We evaluated K-ras mutations in codon 12, p53 mutations in exons 5-8, and Gadd45a mutations in exons 1 and 4. Overall, rates of K-ras, p53 and Gadd45 mutations were not statistically different in tumors of patients from Egypt and the US (67.4 vs. 63.4%; 27.3 vs. 36.4% and 9.1 vs. 4.5%, respectively). However, there were distinct differences in the specific types of K-ras and p53 mutations between the 2 groups. In K-ras, G → T transversion mutation was more frequent in the tumors from Egypt than from the US (58.6 vs. 26.9%), whereas G → C transversion was detected in 26.9% of US tumors but none from Egypt (p = 0.003). We also found a trend toward differences in the p53 exons in which mutations occurred, with higher frequency of exon 5 mutation and lower frequency of exon 6 mutation in Egyptian tumors. Logistic regression showed that K-ras G → T transversion mutations and p53 exon 6 mutations were predicted by the country of residence of the patients. Our study identifies that there are differences in the types of mutations found in tumors from pancreatic carcinoma patients in Egypt and the US, and suggests that environmental factors may explain these differences.
KW - International differences
KW - K-ras
KW - Molecular pathology
KW - Pancreatic cancer
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=33747487722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747487722&partnerID=8YFLogxK
U2 - 10.1002/ijc.21986
DO - 10.1002/ijc.21986
M3 - Article
C2 - 16619252
AN - SCOPUS:33747487722
SN - 0020-7136
VL - 119
SP - 1455
EP - 1461
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 6
ER -